Built for the next generation of biotech leaders.
Extend your intelligence using ours. No one dives deeper into dissecting the latest trends than BioCentury, allowing you to better position your company to capitalize on change.
Find licensing and investment opportunities, uncover competitive threats and identify potential partners using our curated database.
Connect with your peers in our global community of C-Suite executives and investors. Our networking events give you unparalleled access to industry leaders who share your need for investments, partnerships and advice.
Explore some of the ways we can help you.
Identify the companies, programs and investors in your defined market
Develop a nuanced understanding of your target sector with data and analysis
Understand trends and issues shaping the future of your target market
Create a refined target list of potential partners from full biopharma universe
Evaluate potential partners by exploring their pipelines, funding, deals and strategies
Prepare for meetings with both data and context
Identify translational science threats in relevant targets, diseases and technologies
Create alerts for product and strategic developments at competing companies
Monitor investments in your therapeutic and technology spaces
Use Company Profiles to identify comparable programs across the industry
Review investing and partnering deals in your pipeline or program space
Understand where your program fits in the industry pipeline
New variant is first real test of biopharma’s adaptability against the virus
Five submissions under FDA priority review
BioCentury This Week podcast also features the latest strategies for optimizing the potency of TCR-based cancer therapies
BioCentury-BayHelix Present: 8th BioCentury-BayHelix China Healthcare Summit - For seven years, the China Healthcare Summit has been building the "Bridge to Innovation" in China. Now, armed with unprecedented funds, Chinese biotechs and medtechs are racing across the Bridge to Innovation.
BioCentury's spotlight on "Real-World Evidence" highlights BioCentury's recent coverage and analysis into the opportunities for Western pharmaceutical companies to accelerate drug development processes in China using the Real World Evidence (RWE) approval pathway.
“When it comes to timely, relevant discussion of complex industry issues, BioCentury provides fact-based, in-depth reporting and analysis, resisting sensationalism and often incorporating multiple perspectives. This allows us as readers to walk away informed, and in some cases, with actionable insights.”
“The quality and depth of BioCentury's reporting and analysis sets them apart from their competitors. BioCentury provides the most intelligent coverage of the pharma and biotech industry.”
“I’ve been a BioCentury reader for eons. I find other sources have good insights around individual companies or events, but few provide intelligent commentary that gives me a comprehensive sense for what’s happening in a broad area. BioCentury’s “context setting” is really value-added and what sets them apart.”
Building sustainable value through new relationships.
Armed with unprecedented funds, Chinese biotechs and medtechs are racing across the Bridge to Innovation.
The 8th BioCentury-BayHelix China Healthcare Summit is a propitious time to showcase how the China story promises to have a lasting impact on the global biopharma industry.
BioCentury and EBD Group are pleased to announce that the 22nd Bio€quity Europe conference will be held in Milan, Italy May 17-18, 2022.
Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs – join the discussion in Milan, plus take advantage of two bonus days of digital 1x1 meetings.